FDA approves J&J’s ICOTYDE for moderate-to-severe plaque psoriasis

CURRENT BRIEF VERSION: Johnson & Johnson said the U.S. Food and Drug Administration approved ICOTYDE (icotrokinra) on March 18, 2026 for moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The drug is an oral IL-23 receptor antagonist, which J&J is positioning as a first-line systemic option in a category long dominated by injectables and, more recently, oral TYK2 inhibitors. The approval follows J&J’s Phase 3 ICONIC program, including placebo-controlled and active-comparator studies against deucravacitinib, with the company reporting strong skin-clearance results and a safety profile that remained close to placebo through 16 weeks. (investor.jnj.com)

Why it matters: This is a human dermatology approval, not a veterinary one, but it’s still relevant for veterinary professionals tracking the broader immunology pipeline. ICOTYDE gives clinicians and pet parents one more example of where inflammatory disease treatment is heading: targeted oral agents designed to compete with injectable biologics on efficacy while offering easier administration. That matters because dermatology and immune-mediated disease innovation in people often shapes investor interest, platform validation, and future translational work across species. It also strengthens Johnson & Johnson’s psoriasis franchise, where the company already markets TREMFYA (guselkumab) and has been expanding pediatric IL-23 positioning, even as other oral psoriasis programs advance — including Takeda’s zasocitinib, which reported Phase 3 LATITUDE data at AAD 2026 showing superiority to placebo and apremilast and plans for regulatory submissions beginning in Takeda’s fiscal 2026. (investor.jnj.com)

What to watch: Watch for U.S. launch uptake, payer coverage, label details in Drugs@FDA, and whether J&J can extend icotrokinra into inflammatory bowel disease and other IL-23-mediated conditions. It is also worth watching the competitive oral psoriasis field: Takeda said its Phase 3 LATITUDE PsO 3001 and 3002 trials in 693 and 1,108 adults showed strong Week 16 skin responses, improvement through Week 24, and durability beyond a year, setting up a likely new rivalry in oral systemic psoriasis care. (jnj.com)